直接作用抗病毒治疗失败后再治疗对 HCV 基因 1-3 型感染患者的疗效。
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
机构信息
Department of Internal Medicine 1, University Hospital Frankfurt, Goethe University, Frankfurt, and German Center for Infection Research (DZIF), External Partner Site, Frankfurt, Germany.
Department of Internal Medicine I, University of Bonn, Bonn, and German Center for Infection Research (DZIF), Partner Site, Cologne-Bonn, Germany.
出版信息
Clin Gastroenterol Hepatol. 2021 Jan;19(1):195-198.e2. doi: 10.1016/j.cgh.2019.10.051. Epub 2019 Nov 6.
Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options. Data on retreatment of DAA failure patients using first-generation DAAs are limited. Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure. However, this and other second-generation regimens are not available in many resource-limited countries or are not reimbursed by regular insurance, and recommendations regarding the selection of retreatment regimens using first-generation DAAs are very important. This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a DAA combination therapy.
丙型肝炎病毒感染可导致慢性肝脏疾病、肝硬化和肝细胞癌。通过联合直接作用抗病毒药物（DAAs），可实现高持续病毒学应答率（SVR）。在 DAA 治疗失败后，常观察到耐药相关替代（RASs），特别是非结构蛋白 5A（NS5A）RASs 可能影响再治疗选择。使用第一代 DAA 治疗 DAA 治疗失败患者的再治疗数据有限。最近，批准了第二代蛋白酶和 NS5A 抑制剂加索非布韦（voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]）用于 DAA 治疗失败后的再治疗。然而，在许多资源有限的国家，第二代方案并不适用或不受常规保险报销，因此使用第一代 DAA 选择再治疗方案的建议非常重要。本研究旨在分析 DAA 联合治疗失败后使用第一代 DAA 进行再治疗的患者。
Zotero 插件